ArticleFrontiers in neurology
Early neural shift detection using functional magnetic resonance imaging: a pilot study with Parkinson's disease patients undergoing istradefylline and hybrid assistive limb interventions.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) presents with not only motor symptoms but also non-motor features, including cognitive impairment. Although conventional assessments usually require extended observation periods to detect functional changes, more sensitive measures may enable the detection of changes over shorter intervals. Istradefylline, an adenosine A2A receptor antagonist, and the Hybrid Assistive Limb (HAL) device are emerging therapeutic options for PD. However, their short-term functional effects remain unclear, especially when assessed using traditional clinical and neuropsychological tools. Methods: We enrolled six PD patients (Hoehn and Yahr stages II-III) in our prospective, single-center study. Three patients received istradefylline for 1 month in addition to stable antiparkinsonian medication, and three underwent a 2-week HAL-assisted rehabilitation program while continuing their usual medication. Functional magnetic resonance imaging (fMRI) scans and a battery of clinical, cognitive, mood, sleep, and quality of life assessments were conducted at baseline and follow-up (2 weeks for the HAL-assisted rehabilitation group and 1 month for the istradefylline group). We compared the changes in task-related fMRI activation and traditional clinical endpoints. Results: All six patients completed the study without serious adverse events. After 1 month of istradefylline treatment, fMRI findings showed increased activation in multiple brain regions associated with motor and cognitive control. In contrast, clinical outcome measures (including cognitive, motor, mood, sleep, and quality-of-life scores) showed no significant improvement at follow-up in either the istradefylline group or the HAL-assisted rehabilitation group. Conclusion: Short-term istradefylline administration elicited measurable changes in brain activation patterns without corresponding clinical or cognitive gains, which suggests that fMRI may serve as a more sensitive biomarker of early, subthreshold neural adaptations than conventional assessments. However, these findings must be interpreted with caution due to the small sample size and exploratory nature of the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.